Mehmet Sitki Copur, MD, on Inadequacies of the Clinical Trials System Highlighted by COVID-19
The expert oncologist/hematologist spoke with CancerNetwork® about the challenges brought to light by the current pandemic.
In an article published in the journal Oncology, Aline Bobato Lara Gongora, MD, medical oncologist and preceptor of the Medical Oncology Fellowship at Hospital Sírio-Libanês in São Paulo, Brazil; Deni Leonardo Fontes Jardim, MD, PhD, medical oncologist at Hospital Sírio-Libanês; and Diogo A. Bastos, MD, genitourinary oncologist at Hospital Sírio-Libanês and Instituto do Cancer do Estado de São Paulo, discussed policies which should be implemented to the current clinical trials system as a result of the coronavirus disease 2019 (COVID-19).
Based on observations made throughout the pandemic thus far, the team recommended the oncology research community implement formal policies based on the guidance given from regulatory agencies, with the goal of minimizing the risks of COVID-19 infection while maintaining appropriate oncologic treatments for patients during this pandemic.
“Regulatory agencies have formalized recommendations to help guide the research community,” the authors wrote. “Research institutions ultimately should write their own guidance materials, considering their site’s COVID-19 epidemiology and access of staff and patients to technologies, and discussions with their trials’ sponsors and their IRB/IEC should be ongoing.”
In an accompanying commentary, Mehmet Sitki Copur, MD, a medical oncologist/hematologist at Morrison Cancer Center of Mary Lanning Healthcare and a professor at the University of Nebraska Medical Center, explained the inadequacies of the current clinical trials system highlighted by the COVID-19 pandemic.
Speaking further about these challenges in an interview with CancerNetwork®, Copur specifically discussed difficulties surrounding enrollment and protocol adherence difficulties, needing to reduce patient visits, staffing constraints, and limited availability of ancillary services.
This segment comes from the CancerNetwork® portion of the MJH Life Sciences Medical World News, airing daily on all MJH Life Sciences channels.
This study presents a male breast cancer case with a germline BRCA2 mutation and discusses the epidemiologic, pathologic, and clinical characteristics along with treatment and follow-up recommendations in view of our recent understanding of the disease.
Oncology Peer Review On-The-Go: COVID-19, Cancer, and the Potential of mRNA Vaccines
March 30th 2021Mehmet Sitki Copur, MD, discussed his article in the Journal ONCOLOGY® focusing on COVID-19, messenger RNA vaccines, and the excitement surrounding its integration into the future of cancer treatment.
ABSTRACT: Breast metastasis from extramammary malignancy is rare, with a reported incidence rate of 0.4% to 1.3% in the published literature. The primary malignancies that most commonly metastasize to the breast are leukemia, lymphoma, and malignant melanoma. Here, we report a very rare case of metastatic EGFR-mutated non–small cell lung cancer (NSCLC) in the breast detected by screening mammography. The patient had initially been diagnosed with a clinical stage IIIA NSCLC and had been treated with neoadjuvant chemoradiation followed by curative-intent surgery. Several interesting aspects of the case, along with a discussion of evolving adjuvant and frontline metastatic management options in EGFR-mutated NSCLC, will be presented.
Locally Advanced Gastrointestinal Stromal Tumor in a 33-Year-Old Woman Seeking to Conceive
ABSTRACT Gastrointestinal stromal tumors (GISTs) are rare neoplasms of the gastrointestinal tract. They commonly present with nonspecific symptoms and thus are often discovered incidentally. They are best identified by CT scan and most stain positive for CD117 (C-Kit), CD34, and/or DOG-1. Several risk stratification classification systems have been developed based on tumor size, mitotic rate, location, and perforation. Traditional chemotherapy and radiation therapy have been very ineffective, making surgery the mainstay of treatment. The discovery of mutations associated with these tumors has revolutionized the treatment approach. Imatinib mesylate, a selective tyrosine kinase receptor inhibitor, used as adjuvant or neoadjuvant therapy, has greatly improved the morbidity and mortality associated with GISTs. As the survival of patients has increased with the long-term use of targeted therapies, quality-of-life issues now have become much more relevant and have come to the forefront of care. We present a young woman who was successfully treated for GIST but now faces associated long-term adverse effects of imatinib, including the challenge of preserving fertility and the potential for childbearing.
